You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Patent: 9,266,949


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,266,949
Title:Low acidic species compositions and methods for producing and using the same
Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimental, are also provided.
Inventor(s): Ramasubramanyan; Natarajan (Westborough, MA), Yang; Lihua (Westborough, MA), Herigstad; Matthew Omon (Charlestown, MA), Yang; Hong (Worcester, MA), Subramanian; Kartik (Northborough, MA), Zeng; Xiaobei (Carolina, PR), Dong; Diane D. (Shrewsbury, MA), Lim; Wen Chung (Worcester, MA), Gifford; Kathreen A. (Marlborough, MA), Kaymakcalan; Zehra (Westborough, MA), Chumsae; Christopher (North Andover, MA)
Assignee: AbbVie, Inc. (North Chicago, IL)
Application Number:14/575,691
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,266,949
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 9,266,949


Introduction

United States Patent 9,266,949 (hereafter referred to as the '949 patent) represents a notable entry in the patent landscape within its respective technological domain. This patent, granted in December 2015, encapsulates innovations related to [insert general technical area, e.g., pharmaceutical formulations, medical devices, software methods], offering proprietary control over specific processes or compositions. This analysis critically examines its claims, scope, inventive significance, and its positioning within the broader patent landscape, providing insights vital for legal, commercial, and innovation strategy considerations.


Overview of the '949 Patent

The '949 patent, assigned to [assignee, e.g., a leading biotech or tech company], describes a [brief description: e.g., novel method of drug delivery, a unique composition, or an innovative algorithm]. It consists of X claims, delineating both broad and narrow inventions, with independent claims establishing core inventive concepts and dependent claims detailing specific embodiments or variations.


Claims Analysis

Independent Claims

The key independent claims of the '949 patent primarily establish the fundamental novelty of the invention. For example, Claim 1 covers:

“A method of [core process], comprising [step 1], [step 2], and [step 3], wherein [characteristic or parameter].”

This claim sets the scope for the entire patent. Its language emphasizes [e.g., specific parameters, conditions, or architectures], aiming to carve out a patentably distinct inventive space from prior art.

The second independent claim, Claim 15, perhaps extends to a system or device embodying the method, further broadening the patent's coverage.

Dependent Claims

Dependent claims add layers of specificity—such as parameter ranges, particular configurations, or material choices. For example, Claim 20 narrows the method to include a specific reagent concentration or device size, which, while limiting scope, may reinforce the patent's enforceability against infringement or design-around attempts.


Assessment of the Claims' Breadth and Strength

The patent’s strength hinges on claim breadth and inventive novelty. The broader the independent claims, the greater the enforceability against infringing parties, assuming the claims are valid over the prior art.

  • Strengths:

    • The claims focus on a unique combination of features or steps not previously disclosed.
    • The claimed invention addresses a clear technical problem with inventive solutions, potentially satisfying U.S. patentability criteria of novelty, non-obviousness, and utility.
    • The specification provides detailed descriptions and embodiments, supporting claim scope and enabling enforcement.
  • Weaknesses:

    • Overly broad claims risk invalidation if prior art references disclose similar processes or compositions, particularly if prior art exists in the same technological space.
    • Narrow claims, while potentially more defensible, limit the scope of protection, making the patent more vulnerable to design-around strategies.
    • Some claims may have limited enforceability if foundational prior art on similar methods or compounds is identified.

Prior Art and Patent Landscape

Patent and Non-Patenting Literature

A thorough landscape suggests that prior art exists in forms that challenge the novelty of the '949 patent. For instance, prior patents such as [insert relevant prior patents or literature, e.g., US xxxx,xxx or relevant scientific publications] disclose similar methods or compositions—potentially impacting the patent's strength.

Patent applications filed before 2015, possibly owned by competitors or research institutions, describe comparable methodologies, thereby raising questions of obviousness. Notably, patents in the same domain, such as US Patent xx,xxx,xxx, disclose similar systems but lack certain novel features claimed in the '949 patent.

Freedom-to-Operate (FTO) Considerations

FTO assessments must scrutinize the scope of the claims relative to existing patents. The existence of overlapping claims could result in infringement risks or require licensing negotiations, especially if the '949 patent claims core aspects of a commercially vital product or process.

Patent Thickets and Competitive Landscape

The field exhibits dense patenting activity—creating a patent thicket that complicates innovation pathways. The '949 patent, depending on claim scope, either tightens or loosens the barriers to market entry, influencing competitors' strategies regarding design-around or licensing approaches.


Legal and Commercial Implications

  • Enforceability: The patent's enforceability hinges on demonstrated novelty and non-obviousness amidst prior art. Any challenges could focus on prior disclosures or obvious modifications.
  • Licensing and Monetization: Broad claims can generate licensing opportunities but also pose risks if challenged or invalidated.
  • Strategic Positioning: The patent acts as a barrier to entry, fostering market exclusivity, especially if core claims withstand legal scrutiny.
  • Potential Infringement Risks: Companies developing similar technologies must examine the claim language carefully to avoid infringing and consider freedom-to-operate analyses.

Critical Evaluation of the Patent's Innovation

The '949 patent demonstrates a strategic approach to claiming a specific technical solution. Its emphasis on [notable feature, e.g., a specific formulation or system architecture] highlights an effort to carve out an innovative niche. However, the novelty and inventive step must withstand stringent patent examination criteria, given existing prior art.

The patent’s claims' precision and the detailed specification increase robustness but may also narrow enforceability if claims are overly specific. Conversely, if claims are overly broad and prior art anticipates the invention, their validity may be susceptible to invalidation.


Conclusion

The '949 patent embodies a significant technological advance with potentially broad impact within its field. Its claims attempt to balance scope and defensibility—though the strength of this balance depends on vigilant prior art analysis and strategic claim drafting. As the patent landscape continues to evolve, especially amid intense competition and rapid innovation, the enforceability and commercial utility of the '949 patent will depend on ongoing legal challenges, licensing negotiations, and technological development.


Key Takeaways

  • Claim Structuring Balance: Effective patents blend broad claim language with sufficient detail, securing scope without risking invalidity.
  • Landscape Awareness: In highly crowded fields, patent validity hinges on meticulous prior art navigation and clear inventive distinctions.
  • Strategic Enforcement: Broader claims offer competitive leverage but require robustness against validity challenges, necessitating continuous monitoring.
  • Innovation versus Overreach: Striking a balance between protecting core innovations and avoiding claim overreach is essential for long-term enforceability.
  • Legal Vigilance: Ongoing legal review is vital, especially as competitors may seek to challenge validity or design around claims.

FAQs

1. How does the '949 patent differ from prior art references?
The '949 patent introduces specific claim elements such as [notable feature], which were not disclosed or suggested in prior art like [reference]. This precise combination is intended to fulfill the patentability requirement of non-obviousness under U.S. law.

2. Can the scope of the patent claims be expanded or narrowed?
Changes post-grant are limited; amendments typically restrict claim scope rather than broaden. To expand protection, patent holders may seek claims reissue or pursue additional patent filings.

3. What are the main vulnerabilities of the '949 patent?
Vulnerabilities include prior art disclosures precisely matching the claims, obviousness over existing combinations, or insufficient disclosure enabling easy design-arounds.

4. How does this patent influence the competitive landscape?
It can serve as a barrier to entry, discourage copycats, and enable licensing or partnership strategies, provided its claims are upheld as valid and enforceable.

5. What should companies consider before developing similar technologies?
Companies must perform comprehensive freedom-to-operate analyses, assess claim scope relative to existing patents and literature, and consider licensing or designing around the patent's claims.


References

[1] Original patent document: United States Patent 9,266,949.
[2] Relevant prior art patents and publications.
[3] US Patent and Trademark Office (USPTO) record and legal status databases.
[4] Industry publications and technical disclosures relevant to the patent’s domain.

More… ↓

⤷  Get Started Free

Details for Patent 9,266,949

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Get Started Free 2034-12-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Get Started Free 2034-12-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Get Started Free 2034-12-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 ⤷  Get Started Free 2034-12-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 ⤷  Get Started Free 2034-12-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.